Navigation Links
The Leukemia & Lymphoma Society Available to Comment on FDA Approval of Seattle Genetics' Adcetris, First New Treatment for Hodgkin Lymphoma Since 1977
Date:8/19/2011

WHITE PLAINS, N.Y., Aug. 19, 2011 /PRNewswire/ -- Today the Food and Drug Administration (FDA) approved Seattle Genetics' Adcetris to treat two types of rare blood cancers – Hodgkin lymphoma and anaplastic large cell lymphoma (ALCL).

(Logo: http://photos.prnewswire.com/prnh/20110215/NY48642LOGO)

The drug is approved for Hodgkin lymphoma patients after failure of a stem cell transplant or two chemotherapy treatments and for ALCL patients after failure of at least one multi-agent chemotherapy treatment.

"This is a great advance for patients battling both of these diseases," said Hildy Dillon, Senior Vice President of Patient Services for The Leukemia & Lymphoma Society. "These are both considered very curable diseases but there is a population of patients from both diseases for whom treatment has not been effective."

Hodgkin lymphoma has an 86 percent survival and ALCL has an 80 percent cure rate.

"But for those people who don't respond well these can be very difficult cancers to cure. This advance gives new hope to that group of patients," Dillon said.

Dillon added that Seattle Genetics should be commended for investing in a therapy for a very small subgroup of patients who don't respond to standard therapy and for whom there were very limited options until now.

There are nearly 9,000 new cases of Hodgkin lymphoma diagnosed each year and 3,000 new cases of ALCL, and both diseases primarily impact children in their late teens and young adults.  Adcetris is a targeted therapy linking a tumor-targeting antibody to a chemotherapy drug with the goal of limiting side effects.

About The Leukemia & Lymphoma Society

The Leukemia & Lymphoma Society® (LLS) is the world's largest voluntary health agency dedicated to blood cancer. The LLS mission: Cure leukemia, lymphoma, Hodgkin's disease and myeloma, and improve the quality of life of patients and their families. LLS funds lifesaving blood cancer research around the world and provides free information and support services.

Founded in 1949 and headquartered in White Plains, NY, LLS has chapters throughout the United States and Canada. To learn more, visit www.LLS.org or contact the Information Resource Center at (800) 955-4572, Monday through Friday, 9 a.m. to 6 p.m. ET. www.LLS.org.

For LLS Contact:
Andrea Greif
Work: 914-821-8958
Cell: 914-772-3027
andrea.greif@lls.org


'/>"/>
SOURCE The Leukemia & Lymphoma Society
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Perdue Kidd & Vickery Files Lawsuit Against Abbott Laboratories for Inadequate Leukemia and Cancer Warning
2. Recent Study Shows Leukothera™ Combined with Other Agents Has Enhanced Anti-Leukemia Effects
3. Financial Assistance Now Available for People with Acute Lymphoblastic Leukemia
4. Omeros Unlocks Orphan GPCRs Linked to Leukemia and Sleep Disorders
5. Wake Forest Baptist Medical Center and Cornerstone Pharmaceuticals Present Interim Data From Phase I Trial of CPI-613 in Acute Myeloid Leukemia
6. Medco Partners With MolecularMD on Personalized Medicine Program for Chronic Myeloid Leukemia
7. Reportlinker Adds Triple Analysis: Leukemia, Lymphoma and Peptides
8. Reportlinker Adds Triple Analysis: Breast Cancer, Leukemia and Cancer Vaccines
9. Reportlinker Adds Triple Analysis: Leukemia, Lymphoma and Pancreatic Cancer
10. Reportlinker Adds Triple Analysis: Leukemia, Prostate Cancer and Apoptosis
11. Reportlinker Adds Triple Analysis: Colorectal Cancer, Leukemia and Apoptosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... June 23, 2016 Research and ... Excipients Market by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), ... Topical, Coating, Parenteral) - Global Forecast to 2021" ... The global pharmaceutical excipients market is projected ... CAGR of 6.1% in the forecast period 2016 to ...
(Date:6/23/2016)... 23, 2016 Roche (SIX: RO, ROG; OTCQX: ... its Elecsys BRAHMS PCT (procalcitonin) assay as a dedicated ... shock. With this clearance, Roche is the first IVD ... solution for sepsis risk assessment and management. ... and PCT levels in blood can aid clinicians in ...
(Date:6/23/2016)... ANGELES , June 23, 2016 ... CAPR ), a biotechnology company focused ... therapeutics, today announced that patient enrollment in its ... in Duchenne) has exceeded 50% of its 24-patient ... enrollment in the third quarter of 2016, and ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... 2016 , ... Austin residents seeking Mohs surgery services, can now turn to ... Dr. Russell Peckham for medical and surgical dermatology. , Dr. Dorsey brings specialization to ... fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was under the direction of ...
(Date:6/25/2016)... ... 25, 2016 , ... First Choice Emergency Room , the largest network ... the Medical Director of its new Mesquite-Samuell Farm facility. , “We are pleased ... location,” said Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. ...
(Date:6/25/2016)... ... 2016 , ... On Friday, June 10, Van Mitchell, Secretary of the Maryland ... iHire in recognition of their exemplary accomplishments in worksite health promotion. , The Wellness ... & Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire was one of ...
(Date:6/24/2016)... ... ... Those who have experienced traumatic events may suffer from a complex set ... drug or alcohol abuse, as a coping mechanism. To avoid this pain and suffering, ... traumatic event. , Trauma sufferers tend to feel a range of emotions, from depression, ...
(Date:6/24/2016)... ... 24, 2016 , ... The Pulmonary Hypertension Association (PHA) learned ... receive two significant new grants to support its work to advance research and ... by recognizing patients, medical professionals and scientists for their work in fighting pulmonary ...
Breaking Medicine News(10 mins):